Thursday February 2nd 2023



Vivactis Group, the leading European healthcare consultancy group, announces its acquisition of Weber, a Market Access Consultancy firm and specialist in Health Economics and Outcomes Research (HEOR). The acquisition strengthens the Vivactis HM3A Market Access branch by expanding the reach in Market Access throughout Europe, as well as adding complementary HEOR and research science expertise.

Vivactis is an important European healthcare consultancy group involved in several key areas for the healthcare industry such as clinical research, marketing and communication, market access, health economics and public affairs.

“Tactically, Vivactis pursues its strategy of development in services across the value chain of the Pharma and MedTech industry. In this context, we are glad to welcome the Weber team into the Group. By combining Vivactis HM3A and Weber expertise, Vivactis is offering broader Market Access activities for further international development in this key area. This acquisition will also extend synergies with other Vivactis entities”, explains Alain Mahaux, CEO of Vivactis Group.

Weber has a leading position in Spain for global pharma, biotech, and medical device companies with a primary expertise in several therapeutic areas, including rare disease and oncology. With its team of more than 27 highly qualified employees Weber has more than 15 years of experience and has carried out more than 230 projects. The company has an impressive track record in Health Outcome Research including Social Return On Investment (SROI) projects, a type of economic evaluation with the possibility of involving patients. Weber is also a leader in Multicriteria Decision Analysis (MCDA) projects, a structured process that offers greater flexibility to incorporate multiple objectives in comparison to cost-effectiveness analysis or cost-utility analysis. In addition, Weber Foundation allows leading projects to take place in collaboration with patient associations and public entities in order to improve the patient engagement process.

Álvaro Hidalgo, Weber Foundation's President adds: "Our renowned expertise and strong presence in Spain and Portugal is a natural fit for the HM3A Market Access branch within the Vivactis group. This partnership will enable our team to continue scaling our services for clients. For Weber, joining a group like Vivactis is a great opportunity to add value in an international environment. The union with the companies of the Vivacits Group, especially with Vivactis HM3A, will allow us to offer market access, health economics and pharmacoeconomics services that favour the incorporation of health innovation in the Spanish National Healthcare system. Moreover, the internationalisation of the Weber Foundation, focused on patients, will position the Vivactis group as one of the world references in research on health outcomes and accessibility of treatments."

Alexandra Ivanova, Weber's General Manager concludes: "We are proud to be a member of an international independent group. We are thrilled to share expertise and synergies with Vivactis HM3A to form the new international division ‘Vivactis Market Access’. We will work hard to extend our know-how to all the Vivactis Agencies and become a leader in Market Access and HEOR at an international level.”